Denmark Anti-Infective Agents Market Size & Outlook
- Pharmaceuticals
- Infectious Disease Treatment
- anti infective agents market
- Infectious Disease Treatment
Global Market
Related Markets
Ask a question about the anti infective agents market
Denmark anti-infective agents market highlights
- The Denmark anti-infective agents market generated a revenue of USD 817.6 million in 2025 and is expected to reach USD 882.7 million by 2033.
- The Denmark market is expected to grow at a CAGR of 1.5% from 2026 to 2033.
- In terms of segment, antivirals was the largest revenue generating type in 2025.
- Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
Anti-infective agents market data book summary
| Market revenue in 2025 | USD 817.6 million |
| Market revenue in 2033 | USD 882.7 million |
| Growth rate | 1.5% (CAGR from 2026 to 2033) |
| Largest segment | Antivirals |
| Fastest growing segment | Antifungals |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibacterials, Antivirals, Antifungals |
| Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
Other key industry trends
- In terms of revenue, Denmark accounted for 0.6% of the global anti-infective agents market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, UK anti-infective agents market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 9,148.0 million by 2033.
Denmark's anti-infective agents market is experiencing growth, fueled by innovation and increased investments aimed at addressing rising antimicrobial resistance (AMR) and infectious diseases. In December 2022, F2G announced that the FDA had accepted its New Drug Application for olorofim, intended for the treatment of fungal infections.
The New Drug Application submission is supported by promising results from an ongoing Phase 2b open-label study involving 100 patients with fungal infections who have few or no existing treatment options.
No credit card required*
Publish Date: Jun 25, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti Infective Agents Market
Anti Infective Agents Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| B. Braun | View profile | 10001+ | Chapeltown, Sheffield, United Kingdom, Europe | www.bbraun.co.uk |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Mankind Pharma | View profile | 10001+ | New Delhi, Delhi, India, Asia | www.mankindpharma.com |
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
Denmark anti infective agents market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-infective Agents Market Outlook will help companies and investors design strategic landscapes.
Antivirals was the largest segment with a revenue share of 69.63% in 2025.
Horizon Databook has segmented the Denmark anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2021 to 2033.
Denmark's anti-infective agents market is experiencing growth, fueled by innovation and increased investments aimed at addressing rising antimicrobial resistance (AMR) and infectious diseases. In December 2022, F2G announced that the FDA had accepted its New Drug Application for olorofim, intended for the treatment of fungal infections.
The New Drug Application submission is supported by promising results from an ongoing Phase 2b open-label study involving 100 patients with fungal infections who have few or no existing treatment options.
- Denmark Anti-Infective Agents Market Type Outlook (Revenue, USD Million , 2021-2033)
- Antibacterials
- Antivirals
- Antifungals
- Denmark Anti-Infective Agents Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Topical
- Others
- Denmark Anti-Infective Agents Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to anti infective agents market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of anti infective agents market databook
- Our clientele includes a mix of anti infective agents market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark anti infective agents market, including forecasts for subscribers. This country databook contains high-level insights into Denmark anti infective agents market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Denmark Anti-Infective Agents Market, 2021-2033 (US$M)
Denmark Type - Anti-infective Agents Market Statistics, 2025 - 2033 (US$M)
